Synthetic Biology SaaS: Why India Needs Usage, Not Subscriptions
Synthetic biology software in India faces a false choice between subscriptions and usage-based pricing. The data shows usage models generate 2.3x higher NRR in this sector. Subscription billing fails because biotech workflows are irregular and unpredictable.
Get 1 unfair insight every week from India's startup ecosystem.
Read by serious founders and investors. No fluff.
Continue reading with Blog Pass
This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.
Amit Tyagi
Founder, AletheiaAI & GP, Fitoor Capital
Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.
Run a fundability check
India's only MRE-backed platform for founders and investors. Analyse your deck, find investors, and validate your raise strategy.
Don’t miss the next one
One insight every week. No fluff.
One contrarian insight. Every week. No generic startup advice.
Join founders and investors building with better information.